| [1] |
张凯. 中国前列腺癌外科治疗专家共识[J]. 中华外科杂志, 2017, 10(55): 721-724．
|
| [2] |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
|
| [3] |
Bubendorf L, Schöpfer A,Wagner U, et al. Metastatic patterns of prostate cancer: An autopsy study of 1589 patients[J]. Hum Pathol, 2000, 31(5): 578-583.
|
| [4] |
Psaila B, Lyden D. The metastatic niche: adapting the foreign soil[J]. Nat Rev Cancer, 2009, 9(4): 285-293.
|
| [5] |
Ojo D, Lin X, Wong N, et a1. Prostate cancer stem-like cells contribute to the development of castration-resistant prostate cancer[J]. Cancers(Basel), 2015, 7(4): 2290-2308.
|
| [6] |
王野, 高旭, 杨庆, 等. 前列腺癌骨转移发生机制的研究进展[J]. 中华泌尿外科杂志, 2015, 36(9): 715-717.
|
| [7] |
Aydemir H, Kumsar Ş. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study[J]. J Urol, 2015, 194(3): 853-854.
|
| [8] |
Crispen PL, Blute ML. Role of cytoreductive nephrectomy in the era of targeted therapy for renal cell carcinoma[J]. Curt Urol Rep, 2012. 13(1): 38-46．
|
| [9] |
Polcher M, Zivanovic O, Chi DS. Cytoreductive surgery for advanced ovarian cancer[J]. Womens Health(Lond), 2014, 10(2): 179-90.
|
| [10] |
Agarwal S, Liu JH, Crisera CA, et al. Survival in breast cancer patients undergoing immediate breast reconstruction[J]. Breast J, 2010, 16(5): 503-509.
|
| [11] |
Qin XJ, Ma CG, Ye DW, et a1. Tumor cytoreduction results in better response to androgen-ablation-a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancer[J]. Urol Oncol, 2012, 30(2): 145-149.
|
| [12] |
Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in clinically non-organ-confined prostate cancer[J]. CurrUrol Rep, 2014, 15(11): 455.
|
| [13] |
Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study[J]. Eur Urol, 2014, 65(6): 1058-1066.
|
| [14] |
Löppenberg B, Dalela D, Karabon P, et al. The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a National Cancer Data Base analysis[J]. Eur Urol, 2017, 72(1): 14-19.
|
| [15] |
Satkunasivam R, Kim AE, Desai M, et al. Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-Medicare analysis[J].J Urol, 2015, 194(2): 378-385.
|
| [16] |
Poelaert F, Verbaeys C, Rappe B, et al. Cytoreductive prostatectomy for metastatic prostate cancer: first lessons learned from the multicentric prospective local treatment of metastatic prostate cancer (LoMP) trial[J]. Urology, 2017, 106: 146-152.
|
| [17] |
Fossati N, Trinh QD, Sammon J, et a1. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study[J]. Eur Urol, 2015, 67(1): 3-6.
|